CYTK

CytokineticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$4.28

-93.9% vs current

Most likely

Base case

50%

Probability

Target price

$3.37

-95.2% vs current

B-

Bear case

25%

Probability

Target price

$2.14

-97.0% vs current

AI sentiment snapshot

Latest data as of 2025-12-10

AI commentary

Market commentary is mixed but tilted toward cautious optimism after recent filings: the 10-Q reiterated cash/runway items and R&D progress while an 8-K noted regulatory interactions that could be binary for value [#10-Q-2025-11-05][#8-K-2025-10-22]. Investor focus centers on upcoming clinical/regulatory milestones and any partnership payments; headlines to watch are trial readouts and FDA decisions [#PIPELINE-2025].

RankAlpha Sentiment AI - 2025-12-10

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventRegulatory interactions / FDA meeting(s)High impact

Company disclosed recent FDA interactions in an 8-K that could clarify regulatory pathway for lead programs; outcome would materially re-rate the stock [#8-K-2025-10-22].

-eventQuarterly operating results / cash-runway update (10-Q)High impact

Q3 2025 filing/earnings provided updated cash runway and R&D guidance; subsequent quarter filings/updates could change financing outlook [#10-Q-2025-11-05].

-catalystClinical readouts for pipeline candidatesHigh impact

Multiple pipeline programs (cardiac/neuromuscular muscle modulators) have pending development milestones; positive/negative readouts would drive significant revaluation [#PIPELINE-2025].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-12-10 • Updated nightlySource: Internal modelMethodology